A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General and Vascular Surgery

StatusActive
Effective start/end date8/08/167/08/21

Funding

  • Baxter Healthcare Corporation: $64,270.50

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research